ROBOTICS & AUTOMATION
Empowering Progress
Up to 25% off Essentials Robotics and Automation titles
Hematopoietic Stem Cell Transplantation for Neurologic Diseases
- 1st Edition, Volume 202 - August 5, 2024
- Editors: Matilde Inglese, Giovanni L. Mancardi
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 2 4 2 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 2 4 3 - 4
Hematopoietic Stem Cell Transplantation for Neurological Diseases (HSCT), Volume 201 provides the latest information on what has been evaluated as a possible therapeutic tool i… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteHematopoietic Stem Cell Transplantation for Neurological Diseases (HSCT), Volume 201 provides the latest information on what has been evaluated as a possible therapeutic tool in severe autoimmune diseases for the last 20 years. In the neurological field, HSCT has been widely investigated for the treatment of multiple sclerosis and evidence is accumulating about its potential use in neuromyelitis optica, stiff person syndrome, myasthenia gravis, and many immune neuropathies. Besides their strong clinical relevance, studies on HSCT in neurological diseases have contributed to new insights on the pathological mechanisms underlying CNS autoimmunity, hence this volume summarizes that research.
- Reviews immunological mechanisms of HSCT and CNS autoimmunity
- Identifies neurological diseases showing treatment efficacy with HSCT
- Includes MS, myasthenia gravis, neuromyelitis optica, and more
- Covers early and late side effects of HSCT
Clinical/translational Neuroscienticists
- Cover image
- Title page
- Table of Contents
- Series Page
- Copyright
- Handbook of Clinical Neurology 3rd Series
- Dedication
- Foreword
- Preface
- Contributors
- Chapter 1 Introduction to HSCT for neurologic diseases
- Abstract
- Introduction
- References
- Chapter 2 Modification of T- and B-cell-associated immuno-pathologic mechanisms in multiple sclerosis by disease modifying therapies: Achievements and opportunities
- Abstract
- Background
- Body Compartments—The Outside
- Body Compartments—The Inside
- The Future of MS Disease-Modifying Therapies
- References
- Chapter 3 The hematopoietic niche and the autoreactive memory in autoimmune disorders
- Abstract
- The Hematopoietic Niche
- Major Components of the Hematopoietic Niches
- Inflammatory Adaptation
- From Immune Cell Progenitors to Autoreactive Memory
- Conclusions and Future Directions
- Acknowledgments
- References
- Chapter 4 The preclinical data and immunologic rationale for hematopoietic stem cell transplantation in autoimmunity
- Abstract
- Immunologic Tolerance and Autoimmunity
- Experimental Models of ADs and Methods of HSCT/BMT Treatment
- The Role of Bone Marrow and Hematopoietic Stem Cells in ADs
- Allogeneic HSCT in Animal Models of ADs
- Autologous and Syngeneic BMT in AD Models (Table 4.1)
- The Question of T-cell Depletion of the BM Graft and the Optimal Conditioning for HSCT/BMT
- Discussion
- References
- Chapter 5 Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis
- Abstract
- Introduction
- Bone Marrow Transplantation in Experimental Models of Autoimmune Diseases
- Bone Marrow Recovery: Definition and Kinetics of Immune Cell Repopulation
- Mechanisms of Immune Cell Recovery
- Reconstitution and Renewal of the Immune System Following AHSCT in MS
- Immunologic Markers of Response to AHSCT
- Immune System Reconstitution and Prolonged Disease Activity Suppression: Conclusive Insights Into the Potential Mechanism of Action of AHSCT
- Acknowledgment
- References
- Chapter 6 Immune reconstitution in rheumatic disease patients after autologous hematopoietic stem cell transplantation
- Abstract
- Introduction
- Autologous Hematopoietic Stem Cell Transplantation
- Basic Mechanisms of Immune Reconstitution in Rheumatic Diseases
- Specific Topics
- Conclusions
- References
- Chapter 7 The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols
- Abstract
- Introduction
- Mobilization
- Conditioning Regimen
- Intensities Face to Face: Is There Evidence of Superior Benefit?
- Conclusions
- References
- Chapter 8 The HSCT procedure (I): Mobilization, collection, manipulation, and cryopreservation of a HSC graft
- Abstract
- Introduction
- Hematopoiesis and Hematopoietic Stem Cell Biology
- Sources of HSC
- Methods of Collection
- Graft Quality Assessment
- Graft Engineering
- Cryopreservation, Storage, and Thawing
- Regulation
- Stem Cell Collection in Autoimmune Diseases
- Conclusions
- References
- Chapter 9 The HSCT procedure (II): Conditioning, hematopoietic stem cell infusion, supportive care, and monitoring
- Abstract
- Introduction
- Conditioning
- Hematopoietic Stem Cell Infusion
- Supportive Care
- Monitoring
- References
- Further reading
- Chapter 10 Early and late complications of hematopoietic stem cell transplantation
- Abstract
- Noninfectious Complications of ASCT
- Early and Late Infectious Complications of ASCT
- Reproductive Issues in Multiple Sclerosis Patients Scheduled for ASCT
- References
- Chapter 11 Hematopoietic stem cell transplantation for multiple sclerosis
- Abstract
- Multiple Sclerosis, Treatment Goals, and Unmet Needs
- AHSCT in MS Patients
- Evidence of Efficacy
- Safety
- Patient Selection and Recommendations
- Conclusions and Future Perspectives
- References
- Chapter 12 Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be reestablished?
- Abstract
- History of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Demographics
- Conclusions
- References
- Chapter 13 Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Is it CIDP?
- Abstract
- Is the Diagnosis of CIDP Correct?
- Electrophysiology (EPS)
- Acquired Peripheral Neuropathies (Table 13.2)
- Inherited Peripheral Neuropathies
- General Dysimmune Neuropathies
- Nodopathies/paranodopathies (Table 13.6; Fig. 13.4)
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Typical vs Atypical CIDP (Table 13.7)
- Criteria for CIDP
- Standard Treatment for CIDP
- Hematopoietic Stem Cell Transplantation for CIDP
- Results of HSCT (Table 13.16)
- Diagnostic Challenges and Errors in the Diagnosis of CIDP
- Conclusions: Pre-HSCT Algorithm
- References
- Chapter 14 HSCT for stiff person syndrome and myasthenia gravis
- Abstract
- Introduction
- Stiff Person Syndrome Spectrum Disorders
- Hematopoietic Stem Cell Transplantation in SPS
- Conclusions
- References
- Chapter 15 Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders
- Abstract
- Introduction
- Rationale for aHSCT in Pediatric MS
- EBMT Registry Data
- Transplant Procedure
- Posttransplant Care
- General Management of the Patient: Specific Aspects for Children
- COVID Considerations in Pediatric Neurologic ADs and aHSCT
- Conclusions
- Acknowledgments
- References
- Chapter 16 HSCT for systemic autoimmune diseases with neurologic involvement
- Abstract
- Introduction
- HSCT for Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
- HSCT in Antiphospholipid Syndrome
- HSCT for Systemic Vasculitides
- HSCT for Neurologic Manifestations in Rare Indications
- Conclusions
- References
- Chapter 17 Hematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy
- Abstract
- Pathophysiology of Cerebral ALD
- Rationale for Hematopoietic Stem Cell Therapy in Cerebral ALD
- Implementing and Optimizing HSCT for Cerebral ALD
- An Alternative Approach to Allogeneic HSCT
- A Milestone but Limitations Remain
- Ex Vivo Lentiviral Gene Therapy for Early-Stage Cerebral ALD
- In Vivo Gene Therapy for Adrenomyeloneuropathy
- Conclusions
- References
- Chapter 18 Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases
- Abstract
- Introduction
- Methods
- Results
- Discussion
- Conclusions
- Acknowledgment
- References
- Chapter 19 The EBMT-ADWP and the CIBMTR
- Abstract
- The European Society for Blood and Marrow Transplantation (EBMT)
- Center for International Blood and Marrow Transplant Research (CIBMTR)
- Conclusions and Future Directions
- Acknowledgments
- References
- Chapter 20 Ongoing randomized clinical trials on HSCT in multiple sclerosis
- Abstract
- Introduction
- Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation vs. Alemtuzumab, Ocrelizumab, Ofatumumab, or Cladribine in Relapsing Remitting Multiple Sclerosis: STAR-MS
- No Evidence of Disease Activity After Hematopoietic Stem Cell Transplantation: NET-MS
- BEst Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis: BEAT-MS
- RCT Comparing Autologous Hematopoietic SteM Cell Transplantation vs. Alemtuzumab, Cladribine, or Ocrelizumab in MS: RAM-MS
- Conclusions
- References
- Index
- No. of pages: 346
- Language: English
- Edition: 1
- Volume: 202
- Published: August 5, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780323902427
- eBook ISBN: 9780323902434
MI
Matilde Inglese
Matilde Inglese is at the University Hospital IRCCS Ospedale Policlinico San Martino Department of Neurology, Genoa, Italy.
Affiliations and expertise
DINOGMI, University of Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, ItalyGM
Giovanni L. Mancardi
Giovanni L. Mancardi is at the Universita di Genova, DINOGMI, in Genova, Italy.
Affiliations and expertise
Universita di Genova, DINOGMI, Genova, ItalyRead Hematopoietic Stem Cell Transplantation for Neurologic Diseases on ScienceDirect